GRANISOL

Post-LOE

granisetron hydrochloride

Inpharmus

ANDAORALSOLUTION

Approved

Feb 2008

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

GRANISOL (granisetron hydrochloride) by Inpharmus is clinical pharmacology granisetron is a selective 5-hydroxytryptamine 3 (5-ht 3 ) receptor antagonist with little or no affinity for other serotonin receptors, including 5-ht 1 ; 5-ht 1a ; 5-ht 1b/c ; 5-ht 2 ; for alpha 1 -, alpha 2 -, or beta-adrenoreceptors; for dopamine-d 2 ; or for histamine-h 1 ; benzodiazepine; picrotoxin or opioid receptors. Approved for nausea and/or vomiting associated with initial, repeat courses of emetogenic cancer therapy, including high-dose cisplatin. First approved in 2008.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Granisetron is a selective 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT 1 ; 5-HT 1A ; 5-HT 1B/C ; 5-HT 2 ; for alpha 1 -, alpha 2 -, or beta-adrenoreceptors; for dopamine-D 2 ; or for histamine-H 1…

Worked on GRANISOL at Inpharmus? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

GRANISOL

Mechanism of Action

Indications (3)